Wikipedia

Combinatorial ablation and immunotherapy

Combinatorial ablation and immunotherapy is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.[1][2][3][4] Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.[2][3] Various ablative techniques are utilized including cryoablation, radiofrequency ablation, laser ablation, photodynamic ablation, stereotactic radiation therapy, alpha-emitting radiation therapy, hyperthermia therapy, HIFU.[5][6][7][8][9] Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving an autologous, in-vivo tumor lysate vaccine and treating metastatic disease.

Combinatorial ablation and immunotherapy
Specialtyoncology

Mechanism of action

edit

Take magnetic hyperthermia for example. By applying magnetic nanoparticle-mediated hyperthermia with a threshold of 43 °C in order not to damage surrounding normal tissues, a significant quantity of heat-shock proteins (HSP) is expressed within and around the tumor tissues, inducing tumor-specific immune responses. In vivo experiments have indicated that magnetic nanoparticle-mediated hyperthermia can induce the regression of not only a local tumor tissue exposed to heat, but also distant metastatic tumors unexposed to heat. Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining immunotherapy (ie: checkpoint inhibitors, CAR-T cell therapy) and vaccine adjuvants (ie: interferon, saponin) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent.[3][10][11][12][13][14]

Ablation therapies

edit

Various local ablation therapies exist to induce necrosis of tumor cells and release tumor antigens to stimulate an immunological response. These ablation therapies can be combined with a systemic immunotherapy:

  • Thermal ablation – local thermal ablation of tumor:
  • Ablation with alpha radiation therapy
    • A new type of ablation therapy that utilizes alpha radiation is now undergoing clinical trials for treatment of several types of solid tumors. Alpha particles are emitted from intratumorally-inserted seeds that have Ra-224 atoms fixed to their surface. When the radium decays, its short-lived daughter isotopes are released from the seeds by recoil energy, disperse in the tumor, and emit high energy alpha particles, which destroy the tumor. This therapy is called "Diffusing Alpha-emitting Radiation Therapy" or DaRT.[15][16]
  • Nanotechnology in thermal ablation and immunotherapy
    • Currently nanotechnologies has been continuously developed for cancer immunotherapy for their versatility in integration of therapeutic and diagnostic (or termed 'theranostic') multimodalities. For example, iron oxide nanoparticles can generate heat under alternating magnetic field (100 kHz to 1 MHz); and they can also be utilized as imaging contrast agents for magnetic resonance imaging (MRI) for visualizing and monitoring the generation, distribution and biological activities of iron oxide nanoparticles. Magnetic nanoparticles can be concentrated to the tumor site via externally applied magnetic field, which is also advantageous in minimizing dose-related side effects. Localized heat can also trigger release of certain anti-cancer immuno-therapeutics loading from the nano-scale cargos if the nanomaterials are heat-responsive. From biological aspect, local heating can in addition significantly increase the extravasation of nanoscale drug carriers from tumor vessels, which enhances the performance of anti-cancer drug delivery to target cancers.

See also

edit

References

edit
  1. ^ Dupuy; et al. (2014). "Thermal ablation of tumours: biological mechanisms and advances in therapy". Nature Reviews Cancer. 14 (3): 199–208. doi:10.1038/nrc3672. PMID 24561446. S2CID 9224039.
  2. ^ a b Mehta, Amol; Oklu, Rahmi; Sheth, Rahul A. (2015). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?". Gastroenterology Research and Practice. 2016: 1–11. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.
  3. ^ a b c "Immunotherapy could transform systemic power of locoregional IO treatments". 2016. Archived from the original on 2020-12-01. Retrieved 2017-05-03.
  4. ^ Dranoff, Glenn (2016). Cancer Immunology and Immunotherapy. Springer. p. 218. ISBN 9783642141362. Archived from the original on 2021-03-17. Retrieved 2021-10-18.
  5. ^ Prof. Yona Keisari. "Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy". Archived from the original on 2018-03-17. Retrieved 2017-05-03.
  6. ^ Ito, A; Tanaka, K; Kondo, K; Shinkai, M; Honda, H; Matsumoto, K; Saida, T; Kobayashi, T (2003). "Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma". Cancer Science. 94 (3): 308–13. doi:10.1111/j.1349-7006.2003.tb01438.x. PMC 11160160. PMID 12824927.
  7. ^ Xiaoming Yang (2016). "Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy". Oncotarget. 7 (40): 65042–65051. doi:10.18632/oncotarget.11346. PMC 5323137. PMID 27542255.
  8. ^ Braiden, V; Ohtsuru, A; Kawashita, Y; Miki, F; Sawada, T; Ito, M; Cao, Y; Kaneda, Y; Koji, T; Yamashita, S (2000). "Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter". Human Gene Therapy. 11 (18): 2453–63. doi:10.1089/10430340050207948. PMID 11119417.
  9. ^ Takeda, Tsutomu; Takeda, Takashi (2016). "Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia". Hyperthermic Oncology from Bench to Bedside. pp. 319–327. doi:10.1007/978-981-10-0719-4_30. ISBN 978-981-10-0717-0.
  10. ^ Zhu, Jun; Zhang, Yan; Zhang, Aili; He, Kun; Liu, Ping; Xu, Lisa X. (2015). "Cryo-thermal therapy elicits potent anti-tumor immunity". Scientific Reports. 6 (1): 27136. doi:10.1038/srep27136. PMC 4891716. PMID 27256519.
  11. ^ Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.Sabel (2005). "Immunologic response to cryoablation of breast cancer". Gland Surg. 3 (2): 88–93. doi:10.3978/j.issn.2227-684X.2014.03.04. PMC 4115762. PMID 25083502.
  12. ^ Machlenkin, A.; Goldberger, O.; Tirosh, B.; Paz, A.; Volovitz, I.; Bar-Haim, E.; Lee, S. H.; Vadai, E.; Tzehoval, E.; Eisenbach, L. (2005). "Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity". Clinical Cancer Research. 11 (13): 4955–4961. doi:10.1158/1078-0432.CCR-04-2422. PMID 16000595. S2CID 15624452. Archived from the original on 2019-08-06. Retrieved 2017-05-04.
  13. ^ Mehta, Amol; Oklu, Rahmi; Sheth, Rahul A. (2016). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response". Gastroenterol Res Pract. 2016: 1–11. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.
  14. ^ Chatterjee, D. K.; Diagaradjane, P.; Krishnan, S. (2012). "Nanoparticle-mediated hyperthermia in cancer therapy". Therapeutic Delivery. 2 (8): 1001–1014. doi:10.4155/tde.11.72. PMC 3323111. PMID 22506095.
  15. ^ Arazi, Lior (2007). "Treatment of solid tumors by interstitial release of recoiling short-lived alpha-emitters". Phys. Med. Biol. 52 (16): 5025–5042. Bibcode:2007PMB....52.5025A. doi:10.1088/0031-9155/52/16/021. PMID 17671351. S2CID 1585204. Retrieved May 24, 2020.
  16. ^ Cooks, Tomer (2008). "Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms". Int. J. Cancer. 122 (7): 1657–1664. doi:10.1002/ijc.23268. PMID 18059026.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Combinatorial_ablation_and_immunotherapy&oldid=1228260485"